Novo Nordisk (NVO) announced that it plans to invest DKK 8.5 billion, translating to approximately $1.2 billion, to set up a new production facility in Odense, Denmark. Per NVO, the new site will include a state-of-the-art production facility and warehouse covering more than 40,000 m². Designed with modularity and flexibility in mind, it will support the production of various product types for rare diseases, including haemophilia, both now and in the future.Novo Nordisk reported that construction has alread ...